Comparison on the prevention of severe influenza between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database -2018/2019 influenza season-

Comparison on the prevention of severe influenza between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database -2018/2019 influenza season- - Comparison on the prevention of severe influenza between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038159

Enrollment

130000

Registered

2019-10-01

Start date

2019-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza virus infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients whose first diagnosis date for influenza (Day 1) was within the enrollment period (1 Oct 2018 - 17 Apr 2019) 2)Patients who were continuously registered in the database for at least 6 months before Day 1 3)Patients who received baloxavir marboxil, oseltamivir, zanamivir or laninamivir on Day 1

Exclusion criteria

Exclusion criteria: 1)Patients who were hospitalized on Day 1 or in the last 90 days before Day 1 2)Patients who received antibiotics on Day 1 or in the last 90 days before Day 1 3)Patients who were diagnosed as pneumonia in the last 3 months before Day 1 4)Patients who died on Day 1 5)Patients who were less than 1 year old on Day 1 6)Patients who received several anti-influenza drugs on Day 1

Design outcomes

Primary

Measure	Time frame
Occurrence of hospitalization	—

Secondary

Measure	Time frame
Occurrence of administration of antibiotics, occurrence of pneumonia, occurrence of additional administration of anti-influenza drugs	—

Countries

Japan

Contacts

Public ContactMasakazu Notohara

Shionogi & Co., Ltd. Pharmacovigilance Department

masakazu.notohara@shionogi.co.jp+81-6-6209-6958

Outcome results